Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • Gilead's Newer Tenofovir Patents

    The company may have found a way to protect its newest HIV franchise for longer than anticipated, perhaps 10 years longer than it suggests in its 10-K (see p. 15), in both the US and EU.

    15 August 2017 | Seeking Alpha
  • Mylan launches 3 HIV generics in Canada

    Mylan has launched three generics for treating HIV in Canada. Among the three launches is the company’s generic of Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate, 200 mg/300 mg), as well as generics of Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate, 600 mg/200 mg/300 mg) and Viread (tenofovir disoproxil, 300 mg).

    11 August 2017 | Drug Store News
  • AbbVie Mavyret Price Threatens Gilead Hepatitis Dominance

    AbbVie could have charged a premium for its broader, faster cure. Its choice to go cheap will make Mavyret a huge bargain relative to Gilead's drugs for many patients. Payers will likely seize on that. The major PBMs have purposefully held off on announcing which HCV drugs they'll cover next year. Gilead will have to offer very large discounts or expect to lose market share.

    07 August 2017 | Bloomberg
  • Mylan to Provide Generic Truvada for U.K. Trial

    The NHS confirmed Thursday that Mylan had won the drug procurement process for a three-year-long implementation trial for pre-exposure prophylaxis, or PrEP, which is used to prevent HIV infection.

    03 August 2017 | Wall Street Journal
  • Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV

    Proven efficacy and durability of darunavir combined with the improved renal laboratory and bone mineral density profile of emtricitabine/tenofovir alafenamide as compared to emtricitabine/tenofovir disoproxil fumarate into one single tablet

    21 July 2017 | Business Wire
  • An arbitrary benchmark for access to new drugs

    Policy is an admission the UK cannot afford to be at the cutting edge.

    11 July 2017 | Financial Times
  • Drug industry to challenge Nice over new cost limits

    The drug industry is taking legal action over limits introduced on expensive new drugs. The public body authorises spending by the NHS on expensive new treatments. In March it announced a new policy to hold back spending on new drugs that might cost more than £20m a year in any of their first three years of use.

    10 July 2017 | BBC Health
  • Drug Company Back on the Hook for Adulterated HIV Drugs

    Gilead told the FDA that it planned to get its FTC from facilities in Canada, Germany, the United States and South Korea. But the Campies claim that Gilead actually used a company called Synthetics China to produce unapproved FTC at unregistered facilities to save money.

    10 July 2017 | Court House News
  • Surprise FDA Approval of Generic Truvada Is a 'Wakeup Call' for Activists

    The surprise approval of generic Truvada (tenofovir disoproxil fumarate and emtricitabine) by the U.S. Food and Drug Administration (FDA) on June 9 left patients, advocates and doctors scrambling to understand exactly when the generic will become available and how much it will cost.

    07 July 2017 | The Body
  • Can Merck knock Glaxo off its HIV perch? Maybe so, one analyst says

    High-profile investor Neil Woodford isn’t the only one worried about GlaxoSmithKline’s HIV prospects.

    06 July 2017 | Fierce Pharma
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.